Faculty Bibliography

Current Procedural Terminology (CPT) codes for electrodiagnostic procedures include codes for nerve conduction studies, nerve tests with preconfigured arrays, reflex tests, electromyography (EMG), and chemodenervation procedures. The codes are updated yearly. For 2012, there are new EMG codes to be used when the patient also receives nerve conduction studies on the same date. Coding for bilateral chemodenervation procedures has also been clarified. The CPT codes for neurologic procedures are not defined to include consultation or other evaluation and management services. When appropriate, codes for these services and skills may be submitted along with the codes for any neurologic procedures.

Smartphones make mobile computing at point of care practical. Smartphones can think, sync, and link. Built-in and user-installed applications facilitate communications between neurologists and their medical colleagues and patients and augment data acquisition and processing in the core medical information domains of patient data, clinical decision support, and practice management. Mobile telemedicine is becoming practical in certain scenarios. Smartphones can improve neurologic diagnosis and treatment, teaching, and research. Patients can benefit from smartphone technology. In addition to enhanced communication, patient education, and social networking, these devices can promote healthy lifestyles, preventive medicine, and compliance and even serve as monitoring and prosthetic devices.

The chronic autoimmune neuropathies are a diverse group of disorders, whose diagnosis and classification is based on the clinical presentations and results of ancillary tests. In chronic inflammatory demyelinating polyneuropathy, controlled therapeutic trials demonstrated efficacy for intravenous gamma-globulins, corticosteroids, and plasmaphereis. In multifocal motor neuropathy, intravenous gamma-globulins have been shown to be effective. In the other immune-mediated neuropathies, there are no reported controlled therapeutic trials, but efficacy has been reported for some treatments in non-controlled trials on case studies. Choice of therapy in individual cases is based on reported efficacy, as well as severity, progression, coexisting illness, predisposition to developing complications, and potential drug interactions

Neurologists are prescribing intravenous immunoglobulin (IVIg) with increasing frequency to treat many neurologic conditions that have a proven or presumed autoimmune or inflammatory pathogenesis. Although IVIg is not FDA approved for any neurologic condition, physicians can safely prescribe it for several disorders with reasonable certainty that the cost for the agent will be reimbursed by third-party carriers. This article discusses present FDA indications for using IVIg, off-label uses of IVIg, policies of third-party payers toward reimbursement, the Local Medical Review Policy of Medicare, coding, billing, and reimbursement for IVIg infusion, and approaches to use when reimbursement is delayed or denied.

Femoral, saphenous, and obturator neuropathies have diverse causes, many of which are iatrogenic. They have overlapping, but distinct, clinical features. Electrodiagnostic testing can distinguish between these disorders and others in the differential diagnosis. Imaging studies may demonstrate the origin of the neuropathy in some cases. Conservative treatment is usually sufficient, but occasionally surgical exploration of the affected nerve is indicated.